Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Prostate cancer

Overexpression of ERG in HGPIN predicts prostate cancer

Nature Reviews Urology volume 11, page 64 (2014)Cite this article

Subjects

Overexpression of ERG protein, owing to TMPRSS2:ERG gene fusion, in the biopsies of men diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN) is associated with progression to prostate cancer. Out of 461 patients with HGPIN who enrolled in a phase III trial of the selective oestrogen receptor modulator toremifene versus placebo, 27 of 51 (53%) men with ERG-positive HGPIN and 143 of 410 (35%) men with ERG-negative HGPIN progressed to prostate cancer within the study period of 3 years.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Park, K. et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J. Clin. Oncol. 10.1200/JCO.2013.49.8386

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Overexpression of ERG in HGPIN predicts prostate cancer. Nat Rev Urol 11, 64 (2014). https://doi.org/10.1038/nrurol.2013.312

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2013.312

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing